950210.KS
Prestige BioPharma Limited [950210.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
950210.KS Stock Summary
Top 10 Correlated ETFs
950210.KS
Top 10 Correlated Stocks
950210.KS
In the News
950210.KS Financial details
Company Rating
-
Market Cap
492.79B
Income
-45.31B
Revenue
348.27M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
66
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-11.3
Forward P/E
-
PEG
1.44
P/S
8489.14
P/B
1.27
P/C
-
P/FCF
-4.89
Quick Ratio
2.05
Current Ratio
2.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-753.98
EPS next Y
-
EPS next Q
-
EPS this Y
-108.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-40.04%
Revenue Q/Q
78.09%
EPS Q/Q
42.81%
-
-
-
-
SMA20
14.79%
SMA50
-2.09%
SMA100
1.88%
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-11%
ROC
-0.13%
Gross Margin
100%
Oper. Margin
-111133%
Profit Margin
-75102%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7940.0-14920.0
52W High
-1.94%
52W Low
+84.26%
RSI
53.09
Rel Volume
1.5
Avg Volume
60.87K
Volume
91.06K
Perf Week
-0.14%
Perf Month
17.04%
Perf Quarter
-14.94%
Perf Half Y
-26.41%
-
-
-
-
Beta
1.151
-
-
Volatility
244.92%, 1072.07%
Prev Close
-1.15%
Price
14630
Change
-4.5%
Company Profile
- Volume Average 60.87K
- Market Capitalization 492.79B
- Employee 66
- CEO Ms. So-Yeon Park
- Headquarters Singapore,SG
- IPO Date 2021-02-09
-
Website
https://www.prestigebiopharma.com 
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.
